Citations

Clear

3138 citation(s) found for "Smith, AM".

Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma
Hill, Brian T. , Winter, Allison , Becnel, Melody , Cerhan, James R. , Link, Brian K. , Maurer, Matthew J. , Fakhri, Bita , Reddy, Prathima, Smith, Stephen D. , Mukhija, Dhruvika , Jagadeesh, Deepa , Desai, Amrita, Alderuccio, Juan Pablo , Lossos, Izidore S. , Mehra, Pooja , Portell, Craig A. , Goldman, Max L. , Calzada, Oscar , Cohen, Jonathon B. , Hussain, Mohammad Junaid, Tiutan, Timothy , Martin, Peter , Kodali, Abhigna, Evens, Andrew M. , Becnel, Melody R , Cerhan, James R , Link, Brian K , Maurer, Matthew , Calzada, Oscar , Martin, Peter , Evens, Andrew M , Hill, Brian , Fakhri, Bita , Portell, Craig A , Nastoupil, Loretta J. , Habermann, Thomas M. , Ghosh, Nilanjan , Caimi, Paolo F. , Kahl, Brad S.

Mayo Clinic

British Journal of Haematology | December 21, 2018 | Volume: 184 | Issue: 4 | Pages: 524-535

10.1111/bjh.15720 | PMID 30575016 Get It

SummaryBendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL, resulting in disparate practice patterns. Prospective trials have shown benefit of MR after R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or R‐CVP (rituximab, cyclophosphamide, vincristine, prednisone), yet recent data from the GALLIUM study comparing outcomes of patients treated with chemotherapy with R or obinutuzumab (G) showed higher than anticipated fatal adverse events with BR/BG. In order to assess the efficacy and tolerability of MR after BR, we retrospectively collected data on 640 newly diagnosed patients treated with FL. We found that patients who achieved partial remission (PR) after ≥4 cycles of BR had improved duration of response (DOR) with MR vs. no maintenance, whereas those in complete remission did not. These findings were confirmed in a validation cohort. In the entire study population, the known fatal adverse event rate after BR was 2·5% and did not significantly differ in those receiving MR versus no maintenance. [Correction added on 14 January 2019, after online publication: The preceding sentence has been corrected in this current version.] Within the limitations inherent to retrospective analysis, these data suggest that FL patients with a PR to BR experience prolongation of remission with MR with an acceptable safety profile.
Cancer rehabilitation as an essential component of quality care and survivorship from an international perspective
Smith, Sean R. , Zheng, Jasmine , Haig, Andrew J. , Silver, Julie , Silver, Julie K. , Cheville, Andrea

Mayo Clinic

Disability and Rehabilitation | December 21, 2018 | Volume: 42 | Issue: 1 | Pages: 8-13

10.1080/09638288.2018.1514662 | PMID 30574818 Get It

Ultrasound-Assisted Combined Spinal-Epidural Anesthesia for Cesarean Delivery in a Parturient With Currarino Triad: A Case Report
Kenevan, Melissa R., Smith, Hugh M. , Olsen, David A. , Kenevan, Melissa R., Sharpe, Emily E.

Mayo Clinic

A&A Practice | December 20, 2018 | Volume: 12 | Issue: 11 | Pages: 393-395

10.1213/xaa.0000000000000941 | PMID 31162165 Get It

Currarino triad is a rare hereditary condition characterized by anorectal malformation, sacral dysgenesis, and a presacral mass. Neuraxial anesthetic techniques pose increased risks to patients with spinal malformations. Ultrasound imaging improves accuracy of intervertebral level identification compared to clinical estimation. We present the case of a parturient with Currarino triad and a low conus medullaris undergoing cesarean delivery where preprocedural magnetic resonance imaging and ultrasound imaging allowed for successful combined spinal-epidural anesthesia to be performed. Despite these measures, however, the patient did develop a high spinal and temporary postoperative dizziness.
Enduring phenotype of episodic status migrainosus in a prospectively identified patient
Smith, Jonathan H.

Mayo Clinic

Cephalalgia Reports | December 20, 2018 | Volume: 1 | Issue: No issue available | Pages: No page available

10.1177/2515816318815226 Get It

Episodic status migrainosus is a previously described migraine variant where the exclusive phenotype is that of relapsing status migrainosus. The majority of cases have been reported based on retrospective chart review. A prospectively identified case fulfilling previously published criteria for episodic status migrainosus is reported, with an enduring pattern of attacks meeting criteria for status migrainosus over a 35-year period. A family history in a maternal aunt of a similar phenotype was noted. This prospectively identified case further validates the existence of episodic status migrainosus as a novel nosologic entity. The family history in our case suggests the possibility of genetic susceptibility. Perspective regarding a potential temporal continuum between acute migraine, status migrainosus, and new daily persistent headache is described. Status migrainosus may occur both as a complication of migraine and in the pure form of episodic status migrainosus.
Short-Term Outcomes Predict Long-Term Satisfaction in Patients Undergoing Laparoscopic Magnetic Sphincter Augmentation
Antiporda, Michael , Jackson, Chloe, Smith, C. Daniel, Bowers, Steven P.

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | December 17, 2018 | Volume: 29 | Issue: 2 | Pages: 198-202

10.1089/lap.2018.0598 | PMID 30556776 Get It

A case of YY1‐associated syndromic learning disability or Gabriele‐de Vries syndrome with myasthenia gravis
Morales‐Rosado, Joel A. , Kaiwar, Charu , Smith, Benn E., Klee, Eric W. , Dhamija, Radhika , Morales-Rosado, Joel A , Dhamija, Radhika

Mayo Clinic

American Journal of Medical Genetics Part A | December 14, 2018 | Volume: 176 | Issue: 12 | Pages: 2846-2849

10.1002/ajmg.a.40626 | PMID 30549423 Get It

AbstractExome sequencing is being used increasingly to evaluate patients with intellectual disability. YY1 is a ubiquitously distributed transcription factor belonging to the GLIKruppel class of zinc finger proteins recently recognized as the causative gene in 23 patients for the Gabriele‐de Vries syndrome. We report a new case with similar features and a novel variant in YY1, in a region of the gene, which has not previously been reported. A 25 year old female was referred to clinical genetics with a diagnosis of autoimmune myasthenia gravis, facial dysmorphism and learning disability. Chromosomal microarray and gene panel test for congenital myasthenic syndrome was negative. Whole exome sequencing (WES) revealed a presumed pathogenic de novo novel, heterozygous, truncating variant in the YY1 gene, c.860_864delTTAAAA, p.Ile287Argfs*3. The Ile287 residue is conserved across species and is situated in the transcription repressor domain of the protein. This variant is novel and lies in a domain of the protein where no previously reported variants occur. The phenotypic features of our case closely match those of the reported patients. Autoimmune myasthenia gravis has not been reported in these patients and may constitute an expansion of this phenotypic spectrum or perhaps more likely a second unrelated diagnosis.
Brain vital signs detect concussion-related neurophysiological impairments in ice hockey
Fickling, Shaun D. , Smith, Aynsley M., Pawlowski, Gabriela, Hajra, Sujoy Ghosh , Liu, Careesa C. , Farrell, Kyle , Jorgensen, Janelle, Farrell, Kyle J , Song, Xiaowei , Stuart, Michael J. , D’Arcy, Ryan C.N.

Mayo Clinic

Brain | December 3, 2018 | Volume: 142 | Issue: 2 | Pages: 255-262

10.1093/brain/awy317 | PMID 30649205 Get It

Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC).
Zvinovski, Filadelfiya , Hudson, Catherine O., Hundley, Andrew F., Evans, Cynthia, Suresh, Anupama , Stephens, Julie , Carpenter, Kristen M. , Ramaswamy, Bhuvaneswari , Reinbolt, Raquel E. , Williams, Nicole , Sardesai, Sagar , Loprinzi, Charles L. , Sardesai, Sagar , Quick, Allison , Noonan, Anne M. , VanDeusen, Jeffrey , Wesolowski, Robert , Stover, Daniel G. , Smith, Karen L. , Faubion, Stephanie S. , Lustberg, Maryam B.

Mayo Clinic

Journal of Clinical Oncology | November 28, 2018 | Volume: 36 | Issue: 34_suppl | Pages: 202-202

10.1200/jco.2018.36.34_suppl.202 Get It

202 Background: Fractional CO2 laser therapy is an emerging treatment for GSM. The objective of this study was to determine the feasibility, tolerability and preliminary efficacy of fractional CO2 laser therapy in BC survivors. Methods: This was a single arm feasibility study of BC survivors with dyspareunia and/or vaginal dryness. Participants received three treatments with office-based fractional CO2 laser on at least 30 day intervals and returned for a one-month follow-up. Feasibility was defined as treatment completion without serious adverse events (SAE) in a minimum of 80% of patients. Primary efficacy was evaluated using the mean change (∆) in the score on the Vaginal Assessment Scale (VAS). Secondary efficacy endpoints included mean ∆ in scores on the Female Sexual Function Index (FSFI) and Urogenital Distress Inventory (UDI). Descriptive statistics (means and 95% confidence intervals (CI) for continuous variables and proportions for categorical variables) were used. Results: The study is ongoing with 65 patients enrolled. To date, 37 patients have completed all study treatments and follow-up. Median age for those who have completed treatment was 57 years (range 34-72). Most were ER/PR positive (78%) and Her 2 negative (81%) with stage I (43%) or II (41%) BC. Ninety-five percent were receiving endocrine therapy, most commonly aromatase inhibitors (73%). No SAEs were reported in the 37 patients who have completed study treatments and their outcomes are as follows. Based on the VAS, 78% reported moderate-severe dyspareunia and 89% reported moderate-severe vaginal dryness at baseline. At follow up, 28% reported moderate-severe dyspareunia and 28% reported moderate-severe vaginal dryness. The VAS score improved from baseline to follow up (mean ∆ 4.1; 95% CI [3.1, 5.1]). Similarly, the FSFI score improved (mean ∆ -10.0; 95% CI [-13.2, -6.9]) and the UDI score improved (mean ∆ -5.7; 95% CI [-10.1, -1.3]). Final efficacy analysis will be reported once all patients have completed all time points. Conclusions: Fractional CO2 laser treatment is feasible and tolerable in BC survivors and may reduce symptom burden from GSM. A randomized controlled trial with sham laser is currently in development. Clinical trial information: NCT03307044.